ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.
about
Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signallingPathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progeniesProteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12.Minireview: the molecular and genomic basis for prostate cancer health disparitiesDifferentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancerTargeted therapies in oncology: in the crosshairs or at the crossroads?Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer.Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistanceGefitinib treatment affects androgen levels in non-small-cell lung cancer patients.Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.Molecular mechanisms involving prostate cancer racial disparity.EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.Exogenous p27KIP1 expression induces anti-tumour effects and inhibits the EGFR/PI3K/Akt signalling pathway in PC3 cells.Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate carcinoma LNCaP cells.Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells.Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
P2860
Q24650935-F9F37DE9-9F7F-4F94-A5E7-F7922293B3B4Q31049380-F8B70FD4-52A3-44F1-9B31-58BC00F530CCQ33205584-281011A4-7B26-41D9-BB3A-6A098A261B07Q33633160-D2DD3FFF-3F2B-422C-AE26-BA23FD804392Q34805223-7F3AA897-350B-4B7F-BC91-6894278AA2D2Q35641209-9ADBECAF-EDF2-4C5F-911E-54DD948AB934Q35848658-6EE98546-B3C2-409F-BEC7-6C6E2F5ABFE7Q36272854-E4CC7757-D55F-4428-9C34-4358E194543BQ36282200-7476E21E-DB05-4679-AA99-9B7A9A5DDEDEQ36615832-D9B59927-3775-4C8C-8506-C86412BBE887Q37230780-65DB6387-3F19-43CB-B43E-2470EA008643Q37418937-39F1B609-9B90-4672-8A1E-08A03328D697Q39372010-9E7DFB5C-7452-4C1E-BC86-F1C8A315EAA1Q39802754-656CF3D6-922F-4B2B-AEB6-11CB47835F70Q40269020-ACEA3515-6BCD-4772-BB78-8D1748BA32C9Q40543731-64D40979-375E-45BA-8071-7E30756BA231Q42818168-FB026135-4FC7-43EA-A96F-965552761EE1
P2860
ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
ErbB1 and prostate cancer: Erb ...... apoptotic effects of LY294002.
@en
type
label
ErbB1 and prostate cancer: Erb ...... apoptotic effects of LY294002.
@en
prefLabel
ErbB1 and prostate cancer: Erb ...... apoptotic effects of LY294002.
@en
P2093
P2860
P356
P1433
P1476
ErbB1 and prostate cancer: Erb ...... apoptotic effects of LY294002
@en
P2093
Frederik Dagnaes-Hansen
Nancy E Hynes
Niels Tørring
P2860
P304
P356
10.1002/PROS.10245
P577
2003-07-01T00:00:00Z